Immuron Limited · ASX:IMC

Immuron — 21st Virtual Investor Summit Microcap Event (November 2024)

19 slides from Immuron's conference presentation, Nov 22, 2024

1. Slide 1: Immuron CEO presentation to 21st Virtual Investor Summit Microcap Event

   a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event Melbourne, Australia, November 22, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our C

2. Slide 2: © Immuren

   © Immuren

3. Slide 3: Immuron Platform Technology

   Immuron Platform Technology Immuron’s proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has the capability of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine

4. Slide 4: © Immuren

   © Immuren

5. Slide 5: References

   References Connor P, Porter CK, Swierczewski B and Riddle MS. Diarrhea during military deployment: current concepts and future directions. Curr Opin Infect Dis. 25(5): 546-54; 2012. Hutton, M.L., Cunningham, B.A., Mackin, K.E. et al. Bovine antibodies targeting primary and recurrent Clostridium diff

6. Slide 6: © Immuren

   © Immuren

7. Slide 7: Virtual Investor Summit Microcap Event, November 2024

   21 November 2024 Steven Lydeamore Chief Executive Officer Virtual Investor Summit Microcap Event NASDAQ: IMRN ASX: IMC

8. Slide 8: Forward-looking statements

   Certain statements made in this presentation are forward - looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to i

9. Slide 9: Executive summary

   3 Executive summary Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases Two commercially available oral immunotherapeutic products – Travelan® and Protect

10. Slide 10: Opportunity to Convert Billion Dollar Traveller's Diarrhoea Market from Relief to Prevention

    4 Opportunity to Convert Billion Dollar Traveller’s Diarrhoea Market from Relief to Prevention by Travelan® Billion Dollar Market Traveller’s diarrhoea treatment market is large and growing at a CAGR of ~7% 1 Industry tailwinds International travel continues to grow Travel to high - risk destination

11. Slide 11: Travelan continued strong sales growth

    5 Travelan® continued strong sales growth Global + Q1 FY2025 AUD$1.5 million up 13% on prior quarter Australia + Q1 2025 AUD$1.0 million up 3% on prior quarter + Secured core ranging in another nine pharmacy banner groups North America + Q1 2025 AUD$0.5 million up 48% on prior quarter + Strongest mo

12. Slide 12: Continued strong sales growth

    6 6 CONTINUED STRONG SALES GROWTH o Global sales increased by 172% in the 2024 fiscal year to a record A$4.90 million compared to A$1.80 million in FY23 o Record monthly sales in October 2024 of $1.49 million o Australia o FY24: a record A$3.75 million; up 223% o Q1, FY25: A$1.01 million o October 2

13. Slide 13: Expansion of Travelan distribution

    7 7 EXPANSION OF TRAVELAN® DISTRIBUTION

14. Slide 14: Consumer marketing activity driving Travelan sales growth

    8 8 CONSUMER MARKETING ACTIVITY DRIVING TRAVELAN® SALES GROWTH We continue to drive awareness, consideration and engagement o Ranging across major retailers (Australia, Canada) o In - store positioning and promotion o Retailer catalogues o Search and social media marketing o Social competitions o Us

15. Slide 15: World first triple mechanism of action for CDI IMM-529

    WORLD FIRST TRIPLE MECHANISM OF ACTION FOR CDI IMM - 529: pre - IND filed with FDA July 2024; successful pre - IND meeting IMM - 529 will be indicated for the treatment of recurrent C. difficile infection Indication / Target Population • Novel antibody - containing therapeutic which neutralizes C. d

16. Slide 16: Immuron's clinical programs – opportunity assessment

    10 10 IMMURON’S CLINICAL PROGRAMS – OPPORTUNITY ASSESSMENT Corporate › Immuron’s development of IMM - 124E (hyperimmune bovine colostrum) as a prescription medication has the potential to address this unmet need › Primary care physicians (PCP)s impressed with clinical efficacy endpoint targets demon

17. Slide 17: Upcoming Milestones

    11 Upcoming Milestones Revenue + Continued quarter on quarter growth from growth drivers + Secured core ranging in another nine Australian pharmacy banner groups + Strongest monthly sales on amazon.com in September 2024 + Secured distribution in ten pharmacy/grocery retailers in Canada + Record mont

18. Slide 18: Contact information

    EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172 STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION:

19. Slide 19: Scientific references

    13 Scientific references Travelan® (IMM - 124E) Scandinavian Journal of Gastroenterology, 46:7 - 8, 862 - 868, DOI: 10.3109/00365521.2011.574726 Travelan® has been shown to reduce both the incidence and severity of ETEC - induced diarrhea in up to 90% of volunteers Military Health System Research Sy

Immuron — 21st Virtual Investor Summit Microcap Event (November 2024) on 6ix